Our resource hub is home to a wealth of articles, stories and videos about managing and living with type 1 diabetes.
Place your order for our free information packs that support adults and children who have been recently diagnosed.
Our researchers are working on different ways to develop a cure for type 1 diabetes - from growing insulin-producing beta cells in labs to hacking the immune system.
Learn about the technologies that can deliver insulin automatically when needed. And discover the next generation of insulins that are currently being developed.
You could win a cash prize of up to £25,000 when you play the Breakthrough T1D lottery. As well as the chance to win great prizes, you’ll also help fund our research to find a cure for type 1 diabetes.
Researchers need your help. By taking part in research studies and clinical trials, you will help them make progress to improve lives and find a cure for type 1 diabetes.
Our ambitious new roadmap is aimed at driving significant advancements in type 1 diabetes research, treatment, and care.
Your donation helps support people living with type 1 diabetes and funds the best treatment and cure research.
We provide a wealth of information and free resources to help you support and empower your patients or students.
Take our free course for schools to learn more about supporting pupils with type 1 diabetes in educational settings.
Home > News & events > News > Draft NICE guidelines propose wider access to glucose monitoring tech
JDRF is delighted that the National Institute for Healthcare and Care Excellence (NICE) has published draft guidelines recommending that all adults with type 1 diabetes should be offered a choice of flash or continuous glucose monitoring (CGM) in England.
The draft guidance also recommends that children with type 1 diabetes are offered CGM in the first instance and if CGM is not suitable, they should then be offered flash monitoring.
Currently, NICE only recommends that flash monitoring or CGM are offered if patients meet certain criteria.
The proposal will now undergo stakeholder consultation before the NICE guidance on type 1 diabetes is updated in March 2022.
The advance follows JDRF’s ongoing work with NICE to expand access to type 1 technology. In 2019, JDRF submitted comments to the NICE stakeholder consultation calling for a change in wording that would require healthcare professionals to ‘offer’ rather than ‘consider’ CGM for people with type 1 diabetes who meet the criteria. This amendment has been incorporated into the draft guidance.
Whilst the recommendations are a positive development, ensuring that Clinical Commissioning Groups (CCGs) and healthcare providers enact the guidance will form a vital part of JDRF’s ongoing advocacy work.
JDRF Policy and Public Affairs Manager, Rachael Chrisp, says: “This is a big step forward and we are hopeful that by spring of next year, these changes will be implemented. We’re proud of the part we’ve played in strengthening NICE guidance on flash and continuous glucose monitoring.
“It’s been a cross-sector effort with outstanding leadership from NHS England’s National Speciality Advisor Professor Partha Kar together with charities such as JDRF, clinicians, researchers and advocates from the type 1 community.
“We know however there is still much to do to ensure that CCGs and healthcare providers take on this guidance so that everyone with type 1 has access to the treatments they want or need across the four nations of the UK.”
NICE guidance applies to England, but is likely to be adopted in Wales and have influence on Scottish and Northern Irish bodies.
JDRF will work with people affected by type 1 diabetes to submit a formal response to the consultation.
You may have heard of a new feature called ‘CamAPS Liberty’, which will soon be available on the CamAPS FX app. This ‘fully closed-loop’ (FCL) mode, when activated; will allow users to remove the need to count carbohydrates before a meal. But what does this mean for people with type 1 diabetes (T1D), and how close are we to removing meal announcement altogether? Here is what we know…
In draft guidance published today, NICE recommends that anyone with type 1 diabetes who is pregnant or planning a pregnancy should be offered pregnancy-specific HCL technology.
Discussing the main themes from this year's Advanced Technologies & Treatments for Diabetes conference – early detection, cellular cures and disease-modifying therapies.
We’re aware of growing concern around insulin supply in the UK, and we want to reassure our community that this is not a general insulin shortage. There is no need to change the type of insulin you use.
